In: Oncogene, 2021, vol. 40, no. 7, p. 1205–1216
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully i mplemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate...
|
In: Current Treatment Options in Oncology, 2015, vol. 16, no. 9, p. 1-13
|
In: European Archives of Oto-Rhino-Laryngology, 2015, vol. 272, no. 12, p. 3825-3831
|
In: European Radiology, 2015, vol. 25, no. 8, p. 2222-2230
|
In: La radiologia medica, 2015, vol. 120, no. 10, p. 959-966
|
In: Langenbeck's Archives of Surgery, 2015, vol. 400, no. 6, p. 675-682
|
In: CardioVascular and Interventional Radiology, 2015, vol. 38, no. 4, p. 1025-1030
|
In: Breast Cancer Research and Treatment, 2015, vol. 150, no. 2, p. 363-371
|
In: European Archives of Oto-Rhino-Laryngology, 2015, vol. 272, no. 7, p. 1725-1731
|
In: Cellular and Molecular Life Sciences, 2015, vol. 72, no. 8, p. 1463-1471
|